Poor
Not Aligned
Patient Risk:
Moderate
Summary
The AI claims largely reference metoprolol indications and dosing/titration patterns for conditions (hypertension, angina, post-MI oral titration, heart failure, atrial fibrillation) and oral formulations that are not supported by the provided FDA label excerpts for metoprolol tartrate injection. Several statements are unsupported and include monitoring/management guidance not present in the excerpts.
Category Scores
Accurate Statements
Metoprolol tartrate and metoprolol succinate are not interchangeable on a milligram-for-milligram basis.
Not supported by provided excerpts (no interchangeability/conversion guidance in the supplied label text).
Metoprolol dosing depends on the patient’s condition and response.
Partially aligned in concept with label requiring monitoring and individualized clinical stability before next steps, but the provided excerpts do not explicitly state this general rule for dosing across listed conditions; not clearly supported.
Unsupported Statements
Dosing of metoprolol depends on whether the patient is using metoprolol tartrate (short-acting) or metoprolol succinate (extended-release).
Provided label excerpts are specific to metoprolol tartrate injection and do not describe dosing differences vs metoprolol succinate or label durations (short-acting/extended-release).
Metoprolol tartrate is taken more often than once daily.
Not supported; provided excerpts do not provide oral dosing frequency for metoprolol tartrate, and focus on IV bolus regimen for acute MI.
Metoprolol succinate is taken once daily.
Not supported; no metoprolol succinate dosing information is present in the provided excerpts.
Metoprolol dosing for high blood pressure is adjusted based on blood pressure and heart rate.
Hypertension indication and corresponding dosing strategy are not present in the provided label excerpts.
Metoprolol dosing for angina is individualized and titrated based on symptom control and heart rate.
Angina indication and titration strategy are not present in the provided label excerpts.
Metoprolol dosing for angina is titrated to reduce angina episodes while avoiding an excessively low pulse.
Angina-specific titration goals and oral titration targets are not present in the provided excerpts.
After myocardial infarction, metoprolol dosing is often started soon after the event.
While the label supports initiating IV immediately after hemodynamic stabilization in a coronary care unit (acute MI setting), it does not support the general wording 'often started soon after the event' without the specified stabilization/monitoring context.
After myocardial infarction, metoprolol dosing is adjusted over time based on tolerance, especially blood pressure and heart rate.
The excerpts describe IV boluses with monitoring and transition to oral 'for dose selection' but do not state this tolerance-based adjustment language.
Metoprolol dosing regimens after myocardial infarction can differ depending on whether the goal is short-term stabilization or longer-term maintenance.
The excerpts describe early IV administration and subsequent 3-month period in clinical studies but do not provide regimens framed as short-term stabilization vs longer-term maintenance.
Metoprolol is sometimes used in heart failure when patients are stable and on appropriate background therapy.
Heart failure use/criteria and background therapy language are not present in the provided excerpts (only 'worsening cardiac failure may occur' guidance is present).
Metoprolol dosing for heart failure typically follows a slow titration approach.
No heart failure dosing/titration approach is provided in the excerpts.
Slow titration of metoprolol in heart failure is intended to reduce side effects such as low blood pressure or bradycardia.
Heart failure titration rationale is not present in the excerpts.
Metoprolol dosing for heart failure involves reaching a target dose used in clinical protocols.
Target-dose language for heart failure is not present in the excerpts.
For atrial fibrillation/flutter, metoprolol dosing aims to control ventricular rate.
Atrial fibrillation/flutter indication and dosing goal are not present in the provided excerpts.
For atrial fibrillation/flutter, clinicians titrate metoprolol to achieve an appropriate heart rate response.
AF/flutter titration guidance is not present in the provided excerpts.
Metoprolol titration in atrial fibrillation/flutter is monitored with attention to dizziness, fatigue, or low heart rate.
AF/flutter-specific monitoring symptoms are not present in the provided excerpts.
Metoprolol succinate is designed to release the drug more slowly.
Not supported; no formulation description is provided in the excerpts (and label excerpts are for metoprolol tartrate injection).
If switching between metoprolol formulations, a clinician provides a conversion/titration plan.
No switching/conversion instructions for formulations are provided in the excerpts; only transition to oral metoprolol after IV in acute MI is mentioned with 'see prescribing information for oral metoprolol for dose selection' (without conversion/titration plan details).
Metoprolol dosing often needs adjustment or pausing if bradycardia occurs.
The label states: 'If severe bradycardia develops, reduce or stop metoprolol tartrate injection.' The AI claim uses 'often' and broader 'pausing' without matching the 'severe bradycardia' specificity.
Metoprolol dosing often needs adjustment or pausing if dizziness or fainting occurs due to low blood pressure.
The excerpt lists hypotension as an adverse reaction and provides general hypotension management only in overdose; it does not provide this dosing adjustment statement tied to dizziness/fainting.
Metoprolol dosing often needs adjustment or pausing if shortness of breath or fatigue worsen beyond expected levels.
The label warns 'worsening cardiac failure may occur' with instructions to increase diuretics and restore stability before next dose, but does not provide the generalized 'shortness of breath or fatigue worsen beyond expected levels' dosing/pausing language.
Metoprolol dosing often needs adjustment or pausing if heart failure symptoms worsen during early titration.
The label does not describe heart failure treatment via titration in these excerpts; it provides specific guidance for worsening cardiac failure: increase diuretics and restore clinical stability before the next dose.
Do not stop metoprolol abruptly without medical guidance.
Abrupt discontinuation guidance is not present in the provided excerpts.
Sudden withdrawal of metoprolol can worsen angina.
Angina is not an indicated condition in the provided excerpts; withdrawal/angina link is not present.
Sudden withdrawal of metoprolol can raise risk of cardiovascular events.
No withdrawal-specific cardiovascular risk language is present in the provided excerpts.
Metoprolol is typically taken consistently at the same times each day.
No oral administration schedule consistency guidance is present in the provided excerpts.
If a metoprolol dose is missed, the usual approach is to take it when remembered unless it is close to the next dose.
Missed-dose instructions are not present in the provided excerpts.
If a missed metoprolol dose is close to the next dose, the usual approach is to skip rather than double.
Missed-dose instructions are not present in the provided excerpts.
Exact instructions for missed doses depend on the metoprolol formulation and the patient’s prescription.
No missed-dose instructions or formulation-dependent missed-dose guidance is present in the provided excerpts.
Contradictions
Important Omissions
For metoprolol tartrate injection acute MI use: specific IV regimen (three 5 mg bolus injections at ~2-minute intervals), requirement to inspect IV solution visually for particulate/discoloration, initiation in a coronary care unit after hemodynamic stabilization, and monitoring of blood pressure, heart rate, and ECG during IV administration.
Importance:
High
Label-specific instruction for worsening cardiac failure: increase diuretics and restore clinical stability before administering the next dose of metoprolol tartrate injection.
Importance:
Moderate
Label-specific bradycardia warning: 'If severe bradycardia develops, reduce or stop metoprolol tartrate injection' (instead of generalized 'often needs adjustment or pausing').
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because most claims are unsupported by the provided label excerpts and include generalized dosing/titration and discontinuation/missed-dose guidance for multiple indications (hypertension, angina, AF/flutter, heart failure) not covered in the provided metoprolol tartrate injection labeling, there is risk of misapplication of dosing/monitoring instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The AI response makes multiple unsupported claims about indications (hypertension, angina, heart failure, AF/flutter) and oral formulation dosing/titration, which are not supported by the provided FDA label excerpts for metoprolol tartrate injection. It also omits key label-specific IV administration details and monitoring requirements for acute MI.
Suggested Improvement
Restrict claims to the provided label excerpts for metoprolol tartrate injection: acute MI indication; IV bolus regimen (three 5 mg doses at ~2-minute intervals after hemodynamic stabilization in a coronary care unit); monitoring (BP, HR, ECG); transition to oral metoprolol with 'see oral prescribing information for dose selection'; and label-specific warnings (reduce/stop for severe bradycardia; increase diuretics/restore stability for worsening cardiac failure). Avoid formulation-specific and other-indication dosing and missed-dose/discontinuation guidance unless supported by the provided label text.